Moderna疫苗在老年人试验中产生抗体

Moderna提交了一项早期试验的新安全数据，该数据首次证明了，Moderna的COVID-19疫苗能刺激老年人的免疫系统。这是一个重要的突破，因为老年人往往不会像年轻人那样对疫苗作出反应。根据该公司的声明，在一项1期试验中，Moderna公司的COVID-19疫苗在老年人（定义为55岁以上人群）体内产生了“始终如一的高水平”中和抗体，这是人体保护性反应的一个关键组成部分，而在它的试验中老年人的抗体水平与年轻成年人的抗体水平相当。Moderna的早期阶段试验结果里包括了20个老年人群的数据。试验里使用了相同剂量的疫苗，Moderna现在正在给受试者做最后阶段的试验。

Moderna Inc. presented new safety data from an early trial that provides the first evidence that its Covid-19 vaccine stimulates the immune systems of older people. In a phase 1 trial, Moderna’s coronavirus vaccine produced “consistently high levels” of neutralizing antibodies -- a key component of the body’s protective response -- in older adults, the company said in a statement. Antibody levels in people more than 55 years old were comparable to those seen in younger adults, the company said. The results from Moderna’s early-stage trial, which include data from 20 people in the older age group, were presented Wednesday to the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. The findings are important because older adults often don’t respond as well to vaccines as younger adults. The trial used the same dose of the vaccine that’s now being given to subjects in a final-stage trial.   source

指尖新闻：高信噪比，一目了然

新冠疫情追踪